"Interferon-gamma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
| Descriptor ID |
D007371
|
| MeSH Number(s) |
D12.644.276.374.440.893 D12.644.276.374.480.615.350 D12.776.467.374.440.893 D12.776.467.374.480.615.350 D23.529.374.440.893 D23.529.374.480.615.350
|
| Concept/Terms |
Interferon-gamma- Interferon-gamma
- gamma-Interferon
- Interferon, Immune
- Immune Interferon
- Type II Interferon
- Interferon, Type II
- Interferon Type II
- Interferon, gamma
|
Below are MeSH descriptors whose meaning is more general than "Interferon-gamma".
Below are MeSH descriptors whose meaning is more specific than "Interferon-gamma".
This graph shows the total number of publications written about "Interferon-gamma" by people in this website by year, and whether "Interferon-gamma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 1 | 3 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 1 | 2 |
| 2003 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2008 | 2 | 0 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2015 | 1 | 3 | 4 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferon-gamma" by people in Profiles.
-
Mycobacterium tuberculosis-specific cytokine responses according to HIV status among household contacts of people with TB. Tuberculosis (Edinb). 2023 03; 139:102328.
-
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial. Lancet Infect Dis. 2022 Oct; 22(10):1472-1483.
-
Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019 09 18; 11(510).
-
Use of QuantiFERON®-TB Gold in-tube culture supernatants for measurement of antibody responses. PLoS One. 2017; 12(11):e0188396.
-
CCR5 expression, haplotype and immune activation in protection from infection in HIV-exposed uninfected individuals in HIV-serodiscordant relationships. Immunology. 2017 08; 151(4):464-473.
-
Vitamin D, D-dimer, Interferon ?, and sCD14 Levels are Independently Associated with Immune Reconstitution Inflammatory Syndrome: A Prospective, International Study. EBioMedicine. 2016 Feb; 4:115-23.
-
Macrophage Inflammatory Protein-1 Beta and Interferon Gamma Responses in Ugandans with HIV-1 Acute/Early Infections. AIDS Res Hum Retroviruses. 2016 Mar; 32(3):237-46.
-
Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study. BMC Infect Dis. 2015 Oct 22; 15:438.
-
Two distinct conformational states of Mycobacterium tuberculosis virulent factor early secreted antigenic target 6 kDa are behind the discrepancy around its biological functions. FEBS J. 2015 Nov; 282(21):4114-29.
-
A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants. Vaccine. 2015 Jun 09; 33(25):2944-54.